Bristol-Myers Squibb (BMY) has achieved simultaneous clinical results and regulatory progress in its core therapeutic areas, including mental illness, cardiovascular disease, and oncology, further validating the competitiveness of its R&D pipeline. Through a wide range of achievements, from the clinical translation of new schizophrenia drugs to the expansion of indications for immunotherapy drugs for cancer, and AI-based diagnostic collaborations, BMY demonstrates a strengthening trend in its medium- to long-term growth momentum.
First, the clinical transition to cappanfuran, a medication for schizophrenia, yielded positive results. Approximately 86% of patients switching from their existing oral atypical antipsychotics completed the 8-week treatment course, with no cases of discontinuation due to inadequate efficacy. PANSS scores improved by -4.2 points in the 4-week dose reduction group and by -3.1 points in the 2-week dose reduction group. Although 49% of patients reported treatment-related adverse events, no serious side effects occurred. The industry notes that it maintained the same safety profile as the previous EMERGENT study.
In the cardiovascular field, AI-based diagnostic technology collaborations have also garnered significant attention. "Viz HCM," co-developed with Viz.ai, is the first FDA-approved AI algorithm to detect hypertrophic cardiomyopathy using a standard 12-lead electrocardiogram, and it has already diagnosed 11 new patients in real-world clinical settings. Furthermore, among patients who tested positive via AI but did not exhibit the phenotype, 13% progressed to disease within approximately 2.7 years. This indicates that BMY's business is expanding into the digital health sector.
Collaboration in the field of neurodegenerative diseases has also expanded. In the joint study with Inscitro on amyotrophic lateral sclerosis (ALS), two new targets were added, and research results were obtained based on TDP-43 abnormalities associated with approximately 97% of ALS patients. In particular, in an iPSC-based motor neuron model, neurogenesis recovery and a reduction in gene abnormalities were confirmed, increasing therapeutic possibilities.
The cardiomyopathy treatment carbamazine showed positive results in a phase 3 trial in adolescents and maintained efficacy and safety in real-world clinical data spanning up to five years. It is currently approved in over 60 countries, and has been used by more than 22,000 patients in the United States. However, due to the risk of reduced left ventricular ejection fraction, it is only available under the REMS program.
The immunotherapy drug nivolumab adds to the expanded indications. It has been approved in the United States for first-line treatment of stage 3 and 4 classical Hodgkin lymphoma in patients aged 12 years and older, and in Europe, its use has been expanded to include relapsed/refractory patients. The phase 3 SWOG 1826 study showed that it reduced the risk of disease progression or death by 58%, but the incidence of serious adverse events was as high as 39%, which was assessed as a burden factor.
The combination therapy with melzidamide, a candidate treatment for multiple myeloma, also significantly improved progression-free survival, demonstrating its clinical value. Its commercial potential is expected to increase further once overall survival data becomes available.
In the field of autoimmune diseases, abuxitinib has received FDA approval for the treatment of psoriatic arthritis. In pivotal clinical trials, its ACR20 response rate reached a maximum of 54%, demonstrating a significant improvement compared to placebo. However, safety concerns inherent to JAK drugs, such as the risk of infection and malignancy, still require continued management.
On the other hand, BMY maintained its quarterly dividend of $0.63 per share, continuing its shareholder return policy. With the first quarter 2026 results, scheduled for release on April 30, approaching, the market is closely watching how the recent clinical and approval results will be reflected in the earnings.
Industry commentators believe that BMY is transforming from a traditional pharmaceutical company into one based on AI and precision medicine. However, safety risks in some pipeline lines and increased competition are cited as potential factors for future stock price volatility.
